73

Oncology
Prevention and treatment of tumors, and caring for cancer patients.
Sub Categories on Oncology
Latest Articles
U.S. incidence of thyroid cancer plateaued in 2009

U.S. incidence of thyroid cancer plateaued in 2009

(HealthDay)—From 2009 to 2016, the incidence of thyroid cancer reached a plateau and possibly started to decline, according to a research letter published in the Dec. 24/31 issue of theJournal o

U.S. incidence of thyroid cancer plateaued in 2009

(HealthDay)—From 2009 to 2016, the incidence of thyroid cancer reached a plateau and possibly started to decline, according to a research letter published in the Dec. 24/31 issue of theJournal o
Cilta-cel Provides Durable Responses in Lenalidomide-Refractory Myeloma After 1 to 3 Prior Lines

Cilta-cel Provides Durable Responses in Lenalidomide-Refractory Myeloma After 1 to 3 Prior Lines

August 28, 2022Kristi RosaCiltacabtagene autoleucel elicited encouraging responses in patients with multiple myeloma who had received 1 to 3 prior lines of therapy and were refractory to lenalidomide.

Cilta-cel Provides Durable Responses in Lenalidomide-Refractory Myeloma After 1 to 3 Prior Lines

August 28, 2022Kristi RosaCiltacabtagene autoleucel elicited encouraging responses in patients with multiple myeloma who had received 1 to 3 prior lines of therapy and were refractory to lenalidomide.
ICI-Treated Synchronous mRCC Is Associated With Negative Survival Outcomes

ICI-Treated Synchronous mRCC Is Associated With Negative Survival Outcomes

July 17, 2023Ashling WahnerPatients with synchronous metastatic renal cell carcinoma who received first-line immunotherapy had worse survival outcomes compared with those with metachronous metastatic

ICI-Treated Synchronous mRCC Is Associated With Negative Survival Outcomes

July 17, 2023Ashling WahnerPatients with synchronous metastatic renal cell carcinoma who received first-line immunotherapy had worse survival outcomes compared with those with metachronous metastatic
Dual-action drug produces positive results in patients with advanced neuroendocrine tumors

Dual-action drug produces positive results in patients with advanced neuroendocrine tumors

byDana-Farber Cancer InstituteCredit: Pixabay/CC0 Public DomainA drug that simultaneously strikes cancer cells' growth circuits and pipeline to the bloodstream produced encouraging results i

Dual-action drug produces positive results in patients with advanced neuroendocrine tumors

byDana-Farber Cancer InstituteCredit: Pixabay/CC0 Public DomainA drug that simultaneously strikes cancer cells' growth circuits and pipeline to the bloodstream produced encouraging results i
Cancer research: Key function of important leukemia gene demystified

Cancer research: Key function of important leukemia gene demystified

by Nina Grötschl,University of Veterinary Medicine—ViennaCredit: Pixabay/CC0 Public DomainThe oncogene EVI1 causes an aggressive type of leukemia, but its exact function has been a mystery. A re

Cancer research: Key function of important leukemia gene demystified

by Nina Grötschl,University of Veterinary Medicine—ViennaCredit: Pixabay/CC0 Public DomainThe oncogene EVI1 causes an aggressive type of leukemia, but its exact function has been a mystery. A re
To improve a promising cancer drug, cut it in half

To improve a promising cancer drug, cut it in half

by Ian Haydon,University of Washington School of MedicineNeoleukin-2/15 can be split into two fragments that reconstitute its activity when combined. a, Splitting strategy for Neo-2/15. Structur

To improve a promising cancer drug, cut it in half

by Ian Haydon,University of Washington School of MedicineNeoleukin-2/15 can be split into two fragments that reconstitute its activity when combined. a, Splitting strategy for Neo-2/15. Structur
FDA approval of 4-drug combination for front-line treatment of metastatic pancreatic cancer

FDA approval of 4-drug combination for front-line treatment of metastatic pancreatic cancer

by Denise Heady,University of California, Los AngelesKaplan–Meier estimates of overall survival (A) and progression-free survival (B) NALIRIFOX=liposomal irinotecan in combination with fluoroura

FDA approval of 4-drug combination for front-line treatment of metastatic pancreatic cancer

by Denise Heady,University of California, Los AngelesKaplan–Meier estimates of overall survival (A) and progression-free survival (B) NALIRIFOX=liposomal irinotecan in combination with fluoroura
With Urological Cancer and COVID-19 Undergoing Elective Surgery at Higher Risk for Mortality

With Urological Cancer and COVID-19 Undergoing Elective Surgery at Higher Risk for Mortality

July 10, 2021Kristi RosaPatients with a urological cancer who were also infected with COVID-19 and undergoing elective surgery for their disease, were found to have a significantly higher likelihood o

With Urological Cancer and COVID-19 Undergoing Elective Surgery at Higher Risk for Mortality

July 10, 2021Kristi RosaPatients with a urological cancer who were also infected with COVID-19 and undergoing elective surgery for their disease, were found to have a significantly higher likelihood o
Study identifies skin microbiome as a factor in stem cell transplants

Study identifies skin microbiome as a factor in stem cell transplants

Study identifies skin microbiome as a factor in stem cell transplantsbyMedical University of ViennaCredit: AI-generated imageOrgan damage occurs in up to 70% of patients in the first few months

Study identifies skin microbiome as a factor in stem cell transplants

Study identifies skin microbiome as a factor in stem cell transplantsbyMedical University of ViennaCredit: AI-generated imageOrgan damage occurs in up to 70% of patients in the first few months
Frontline Eganelisib Triplet Provides Potential Long-term PFS Benefit in Metastatic TNBC

Frontline Eganelisib Triplet Provides Potential Long-term PFS Benefit in Metastatic TNBC

November 15, 2022Kristi RosaThe addition of eganelisib to atezolizumab and nab-paclitaxel demonstrated evidence of a long-term progression-free survival benefit when used as first-line treatment in pa

Frontline Eganelisib Triplet Provides Potential Long-term PFS Benefit in Metastatic TNBC

November 15, 2022Kristi RosaThe addition of eganelisib to atezolizumab and nab-paclitaxel demonstrated evidence of a long-term progression-free survival benefit when used as first-line treatment in pa
Researchers identify molecular characteristics of leptomeningeal melanoma metastases

Researchers identify molecular characteristics of leptomeningeal melanoma metastases

byH. Lee Moffitt Cancer Center & Research InstituteMelanoma in skin biopsy with H&E stain—this case may represent superficial spreading melanoma. Credit: Wikipedia/CC BY-SA 3.0Patients w

Researchers identify molecular characteristics of leptomeningeal melanoma metastases

byH. Lee Moffitt Cancer Center & Research InstituteMelanoma in skin biopsy with H&E stain—this case may represent superficial spreading melanoma. Credit: Wikipedia/CC BY-SA 3.0Patients w
Molecular map reveals insights into the genetic drivers of chronic lymphocytic leukemia

Molecular map reveals insights into the genetic drivers of chronic lymphocytic leukemia

byMassachusetts General HospitalCredit: Unsplash/CC0 Public DomainA newly constructed map of the landscape of genetic changes in chronic lymphocytic leukemia (CLL), a type of cancer of the blood

Molecular map reveals insights into the genetic drivers of chronic lymphocytic leukemia

byMassachusetts General HospitalCredit: Unsplash/CC0 Public DomainA newly constructed map of the landscape of genetic changes in chronic lymphocytic leukemia (CLL), a type of cancer of the blood